About Karyopharm Therapeutics (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:KPTI
- CUSIP: N/A
- Web: www.karyopharm.com
- Market Cap: $501.55 million
- Outstanding Shares: 47,139,000
- 50 Day Moving Avg: $11.02
- 200 Day Moving Avg: $9.83
- 52 Week Range: $6.27 - $14.63
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.61
- P/E Growth: -0.14
- Annual Revenue: $165,999.00
- Price / Sales: 3,021.46
- Book Value: $3.54 per share
- Price / Book: 3.01
- EBITDA: ($112,220,000.00)
- Net Margins: -67,267.47%
- Return on Equity: -70.42%
- Return on Assets: -63.34%
- Current Ratio: 8.32%
- Quick Ratio: 8.32%
- Average Volume: 182,409 shs.
- Beta: 4.16
- Short Ratio: 23.38
Frequently Asked Questions for Karyopharm Therapeutics (NASDAQ:KPTI)
What is Karyopharm Therapeutics' stock symbol?
Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."
How were Karyopharm Therapeutics' earnings last quarter?
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its earnings results on Tuesday, August, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. The company's quarterly revenue was down 95.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.84) earnings per share. View Karyopharm Therapeutics' Earnings History.
When will Karyopharm Therapeutics make its next earnings announcement?
Where is Karyopharm Therapeutics' stock going? Where will Karyopharm Therapeutics' stock price be in 2017?
7 analysts have issued 1-year price targets for Karyopharm Therapeutics' stock. Their forecasts range from $14.00 to $19.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $16.00 in the next twelve months. View Analyst Ratings for Karyopharm Therapeutics.
What are analysts saying about Karyopharm Therapeutics stock?
Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
- 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (7/18/2017)
- 2. Cantor Fitzgerald analysts commented, "Support for KPTI’s DLBCL program (SADAL) could build with a presentation at the EHA (Abstract S469) in June." (5/15/2017)
- 3. HC Wainwright analysts commented, "Although selinexor is still technically on a partial clinical hold in the U.S., due to an omitted table in its most recent investigator's brochure, Karyopharm focused its 4Q call on the steady progress being made in its development across a range of indications. Having received its requested information, we believe the FDA should release the partial clinical hold well in advance of 4/9, and believe this hiccup will have no material impact on enrollment of the selinexor trials. On its call, Karyopharm noted that it had completed enrollment of its Phase 2/3 SEAL trial of selinexor in liposarcoma patients and expects to report topline data in mid-2017. While we do not currently include liposarcoma in our estimates, we note that selinexor had shown promising and durable stable disease outcomes in a Phase 1 study in sarcomas with a better PFS observed than the last prior regimen (19.4 v. 7.7 weeks) with 43% of liposarcoma patients achieving stable disease having a 4+ month response. Separately, Karyopharm provided updates on selinexor in multiple myeloma noting that the expanded STORM trial in penta-refractory myeloma patients was on track to read out in early-2018, the Phase 3 BOSTON trial was expected to start by April, and the Phase 1b/2 STOMP trial was to begin enrollment of a 44- patient Darzalex (daratumumab) combination arm, expected to read out in late-2017/early-2018. As of December, Karyopharm had a cash position of $175.5M, which the company believes sufficient to fund operations through 2018. In 2017, Karyopharm expects its cash burn to be $85-90M. We are maintaining our KPTI price target of $14, based on a sum-of-the-parts DCF consisting of $6 for selinexor in MM, $4 sel in DLBCL, and $4 cash." (3/17/2017)
Who are some of Karyopharm Therapeutics' key competitors?
Some companies that are related to Karyopharm Therapeutics include Athenex (ATNX), Xencor (XNCR), REGENXBIO (RGNX), Retrophin (RTRX), Amarin Corporation PLC (AMRN), Ignyta (RXDX), Intra-Cellular Therapies (ITCI), Reata Pharmaceuticals (RETA), Flexion Therapeutics (FLXN), Akebia Therapeutics (AKBA), Omeros Corporation (OMER), Cytokinetics, Incorporated (CYTK), Revance Therapeutics (RVNC), Alder BioPharmaceuticals (ALDR), La Jolla Pharmaceutical Company (LJPC), CytomX Therapeutics (CTMX), Keryx Biopharmaceuticals (KERX) and ZIOPHARM Oncology (ZIOP).
Who are Karyopharm Therapeutics' key executives?
Karyopharm Therapeutics' management team includes the folowing people:
- Sharon Shacham Ph.D., President, Co-Founder, Chief Scientific Officer, Director
- Michael G. Kauffman M.D. Ph.D., Co-Founder, Chief Executive Officer and Director
- Michael Falvey, Chief Financial Officer, Executive Vice President, Treasurer, Principal Financial Officer, Principal Accounting Officer
- Michael J. Todisco CPA, Vice President - Finance, Assistant Treasurer
- Christopher B. Primiano, Vice President- Corporate Development, General Counsel, Secretary
- Dilara McCauley Ph.D., Vice President - Product Leadership
- Brian Austad Ph.D., Senior Director, Head - Pharmaceutical Sciences
- Ran Frenkel, Chief Development Operations Officer
- Barry E. Greene, Lead Independent Director
- Mikael Dolsten M.D., Ph.D., Director
Who owns Karyopharm Therapeutics stock?
Karyopharm Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Nationwide Fund Advisors (0.22%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza and Ran Frenkel. View Institutional Ownership Trends for Karyopharm Therapeutics.
Who bought Karyopharm Therapeutics stock? Who is buying Karyopharm Therapeutics stock?
How do I buy Karyopharm Therapeutics stock?
Shares of Karyopharm Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Karyopharm Therapeutics' stock price today?
MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Karyopharm Therapeutics stock can currently be purchased for approximately $10.64.
Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||7 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$16.00 (50.38% upside)|Consensus Price Target History for Karyopharm Therapeutics (NASDAQ:KPTI)
Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/18/2017||Royal Bank Of Canada||Reiterated Rating||Buy||$14.00||N/A|
|10/13/2017||Jefferies Group LLC||Reiterated Rating||Buy||N/A|
|10/12/2017||Cantor Fitzgerald||Set Price Target||Buy||$18.00||N/A|
|8/8/2017||Canaccord Genuity||Set Price Target||Buy||$18.00||High|
|7/4/2017||Robert W. Baird||Reiterated Rating||Outperform||$15.00||High|
|3/17/2017||HC Wainwright||Reiterated Rating||Buy||$14.00||Medium|
|10/7/2016||Leerink Swann||Reiterated Rating||Outperform||$18.00||N/A|
|8/30/2016||S&P Equity Research||Lower Price Target||$9.06 -> $7.55||N/A|
|5/27/2016||Raymond James Financial, Inc.||Initiated Coverage||Outperform||$13.00||N/A|
|3/15/2016||Bank of America Corporation||Downgrade||Neutral -> Underperform||$26.00 -> $11.00||N/A|
|3/14/2016||J P Morgan Chase & Co||Lower Price Target||Overweight||$20.00 -> $19.00||N/A|
|3/9/2016||JMP Securities||Lower Price Target||Market Outperform||$58.00 -> $28.00||N/A|
|12/22/2015||FBR & Co||Reiterated Rating||Buy||$20.00||N/A|
Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)Earnings History by Quarter for Karyopharm Therapeutics (NASDAQ KPTI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2017|| || || || || || || || |
|8/8/2017||Q2 2017||($0.64)||($0.64)||$0.23 million||View||Listen|
|5/4/2017||Q1 2017||($0.67)||($0.71)||$0.02 million||$0.07 million||View||Listen|
|3/16/2017||Q4 2016||($0.65)||($0.65)||$0.18 million||$0.05 million||View||N/A|
|11/7/2016||Q316||($0.81)||($0.69)||$0.18 million||$0.05 million||View||Listen|
|8/4/2016||Q216||($0.76)||($0.84)||$0.18 million||$0.06 million||View||N/A|
|3/14/2016||Q415||($0.82)||($0.81)||$0.30 million||$0.03 million||View||Listen|
|11/9/2015||Q315||($0.87)||($0.85)||$0.30 million||$0.08 million||View||Listen|
|8/10/2015||Q215||($0.77)||($0.92)||$0.30 million||$0.15 million||View||Listen|
|3/16/2015||Q414||($0.66)||($0.79)||$0.11 million||$0.02 million||View||Listen|
|11/10/2014||Q314||($0.53)||($0.61)||$0.20 million||$0.02 million||View||N/A|
|8/7/2014||Q214||($0.51)||($0.55)||$0.20 million||$0.02 million||View||N/A|
|5/7/2014||Q1 2014||($0.45)||($0.46)||$0.25 million||$0.17 million||View||N/A|
Earnings Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)
2017 EPS Consensus Estimate: ($2.52)
2018 EPS Consensus Estimate: ($2.44)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Karyopharm Therapeutics (NASDAQ:KPTI)
Insider Ownership Percentage: 14.71%Insider Trades by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Institutional Ownership Percentage: 58.97%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/2/2017||Christopher Brett Primiano||SVP||Sell||1,500||$12.00||$18,000.00|| |
|10/2/2017||Mansoor Raza Mirza||Director||Sell||2,000||$12.00||$24,000.00|| |
|9/15/2017||Christopher Brett Primiano||SVP||Sell||2,000||$11.00||$22,000.00|| |
|9/15/2017||Mansoor Raza Mirza||Director||Sell||2,882||$11.00||$31,702.00|| |
|9/11/2017||Mansoor Raza Mirza||Director||Sell||118||$11.00||$1,298.00|| |
|8/29/2017||Christopher Brett Primiano||SVP||Sell||2,195||$10.00||$21,950.00|| |
|6/26/2017||Christopher Brett Primiano||SVP||Sell||805||$10.03||$8,074.15|| |
|11/14/2016||Ran Frenkel||Insider||Sell||3,309||$10.06||$33,288.54|| |
|6/23/2016||Ltd Chione||Major Shareholder||Sell||18,824||$8.03||$151,156.72|| |
|6/13/2016||Ltd Chione||Major Shareholder||Sell||7,074||$8.51||$60,199.74|| |
|6/9/2016||Ltd Chione||Major Shareholder||Sell||45,541||$9.21||$419,432.61|| |
|6/7/2016||Ltd Chione||Major Shareholder||Sell||40,000||$9.24||$369,600.00|| |
|6/2/2016||Ltd Chione||Major Shareholder||Sell||17,855||$9.65||$172,300.75|| |
|6/1/2016||Ltd Chione||Major Shareholder||Sell||74,664||$9.61||$717,521.04|| |
|5/31/2016||Ltd Chione||Major Shareholder||Sell||17,096||$9.66||$165,147.36|| |
|5/27/2016||Ltd Chione||Major Shareholder||Sell||40,000||$9.58||$383,200.00|| |
|5/26/2016||Ltd Chione||Major Shareholder||Sell||46,122||$9.73||$448,767.06|| |
|5/23/2016||Ltd Chione||Major Shareholder||Sell||93,932||$8.54||$802,179.28|| |
|5/18/2016||Ltd Chione||Major Shareholder||Sell||63,800||$8.15||$519,970.00|| |
|5/16/2016||Ltd Chione||Major Shareholder||Sell||10,400||$8.01||$83,304.00|| |
|5/11/2016||Ltd Chione||Major Shareholder||Sell||31,868||$8.24||$262,592.32|| |
|12/8/2015||Mansoor Raza Mirza||Director||Sell||15,000||$15.01||$225,150.00|| |
|4/7/2015||Ran Frenkel||EVP||Buy||3,000||$31.81||$95,430.00|| |
|4/2/2015||Barry E Greene||Director||Buy||3,000||$29.31||$87,930.00|| |
|4/2/2015||Justin A Renz||CFO||Buy||5,000||$29.71||$148,550.00|| |
|1/12/2015||Deepika Pakianathan||Director||Buy||45,454||$33.00||$1,499,982.00|| |
|1/12/2015||Michael Kauffman||CEO||Sell||50,000||$33.00||$1,650,000.00|| |
|1/12/2015||Sharon Shacham||Insider||Sell||25,000||$33.00||$825,000.00|| |
|12/2/2014||Mansoor Raza Mirza||Director||Sell||10,000||$43.52||$435,200.00|| |
|12/1/2014||Ltd Chione||Major Shareholder||Sell||278,115||$41.92||$11,658,580.80|| |
|11/25/2014||Ltd Chione||Major Shareholder||Sell||242,800||$42.40||$10,294,720.00|| |
|11/19/2014||Ltd Chione||Major Shareholder||Sell||65,968||$40.09||$2,644,657.12|| |
|11/12/2014||Ltd Chione||Major Shareholder||Sell||164,100||$42.83||$7,028,403.00|| |
|11/11/2014||Ltd Chione||Major Shareholder||Sell||54,100||$42.51||$2,299,791.00|| |
|11/10/2014||Ltd Chione||Major Shareholder||Sell||65,000||$43.40||$2,821,000.00|| |
|11/10/2014||Mansoor Raza Mirza||Director||Sell||5,000||$45.05||$225,250.00|| |
|11/6/2014||Ltd Chione||Major Shareholder||Sell||272,784||$42.11||$11,486,934.24|| |
|10/29/2014||Mansoor Raza Mirza||Director||Sell||3,500||$40.05||$140,175.00|| |
|9/26/2014||Marcin Czernik||Major Shareholder||Sell||50,000||$42.54||$2,127,000.00|| |
|9/24/2014||Marcin Czernik||Major Shareholder||Sell||22,498||$40.32||$907,119.36|| |
|9/18/2014||Marcin Czernik||Major Shareholder||Sell||12,347||$40.24||$496,843.28|| |
|9/17/2014||Marcin Czernik||Major Shareholder||Sell||9,569||$40.26||$385,247.94|| |
|9/12/2014||Ltd Chione||Major Shareholder||Sell||4,312||$41.12||$177,309.44|| |
|9/8/2014||Marcin Czernik||Major Shareholder||Sell||35,666||$39.92||$1,423,786.72|| |
|9/4/2014||Marcin Czernik||Major Shareholder||Sell||12,795||$38.07||$487,105.65|| |
|8/27/2014||Marcin Czernik||Major Shareholder||Sell||43,699||$38.80||$1,695,521.20|| |
|8/25/2014||Marcin Czernik||Major Shareholder||Sell||4,389||$38.08||$167,133.12|| |
|8/15/2014||Marcin Czernik||Major Shareholder||Sell||8,027||$39.11||$313,935.97|| |
|8/11/2014||Marcin Czernik||Major Shareholder||Sell||36,979||$37.30||$1,379,316.70|| |
|7/30/2014||Marcin Czernik||Major Shareholder||Sell||21,570||$36.20||$780,834.00|| |
|7/29/2014||Ltd Chione||Major Shareholder||Sell||30,000||$35.20||$1,056,000.00|| |
|7/23/2014||Ltd Plio||Insider||Sell||500,000||$35.54||$17,770,000.00|| |
|7/2/2014||Michael Kauffman||CEO||Sell||200,000||$42.50||$8,500,000.00|| |
|6/18/2014||Sharon Shacham||Insider||Sell||20,000||$41.76||$835,200.00|| |
|6/17/2014||Michael Kauffman||CEO||Sell||20,000||$41.76||$835,200.00|| |
|5/23/2014||Deepika Pakianathan||Director||Buy||114,419||$26.18||$2,995,489.42|| |
|5/13/2014||Paul Brannelly||SVP||Buy||1,000||$28.06||$28,060.00|| |
|11/12/2013||Deepika Pakianathan||Director||Buy||312,500||$16.00||$5,000,000.00|| |
Headline Trends for Karyopharm Therapeutics (NASDAQ:KPTI)
Latest Headlines for Karyopharm Therapeutics (NASDAQ:KPTI)
Loading headlines, please wait.
Karyopharm Therapeutics (KPTI) Chart for Tuesday, October, 24, 2017